DOCSLIB.ORG

21 CFR Ch. II (4–1–01 Edition) § 1308.11

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
21 CFR Ch. II (4–1–01 Edition) § 1308.11 § 1308.11 21 CFR Ch. II (4–1–01 Edition) and on certain order forms issued by (4) Alphacetylmethadol (except levo- the Administration pursuant to alphacetylmethadol also known as levo-alpha- acetylmethadol, levomethadyl acetate, or LAAM) ..... 9603 § 1305.05(d) of this chapter. Applicants (5) Alphameprodine ....................................................... 9604 for procurement and/or individual man- (6) Alphamethadol ......................................................... 9605 ufacturing quotas must include the ap- (7) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta- propriate code number on the applica- phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl- 2-phenylethyl)-4-(N-propanilido) piperidine) ............... 9814 tion as required in §§ 1303.12(b) and (8) Alpha-methylthiofentanyl (N-[1-methyl-2-(2- 1303.22(a) of this chapter. Applicants thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide) ..... 9832 for import and export permits must in- (9) Benzethidine ............................................................. 9606 (10) Betacetylmethadol .................................................. 9607 clude the appropriate code number on (11) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2- the application as required in phenethyl)-4-piperidinyl]-N-phenylpropanamide) ....... 9830 §§ 1312.12(a) and 1312.22(a) of this chap- (12) Beta-hydroxy-3-methylfentanyl (other name: N-[1- ter. Authorized registrants who desire (2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N- phenylpropanamide .................................................... 9831 to import or export a controlled sub- (13) Betameprodine ....................................................... 9608 stance for which an import or export (14) Betamethadol ......................................................... 9609 permit is not required must include the (15) Betaprodine ............................................................ 9611 appropriate Administration Controlled (16) Clonitazene ............................................................ 9612 (17) Dextromoramide ..................................................... 9613 Substances Code Number beneath or (18) Diampromide .......................................................... 9615 beside the name of each controlled sub- (19) Diethylthiambutene ................................................. 9616 stance listed on the DEA Form 236 (20) Difenoxin ................................................................ 9168 (Controlled Substance Import/Export (21) Dimenoxadol .......................................................... 9617 (22) Dimepheptanol ....................................................... 9618 Declaration) which is executed for such (23) Dimethylthiambutene .............................................. 9619 importation or exportation as required (24) Dioxaphetyl butyrate .............................................. 9621 in §§ 1312.18(c) and 1312.27(b) of this (25) Dipipanone ............................................................. 9622 (26) Ethylmethylthiambutene ......................................... 9623 chapter. (27) Etonitazene ............................................................ 9624 (b) Except as stated in paragraph (a) (28) Etoxeridine ............................................................. 9625 of this section, no applicant or reg- (29) Furethidine ............................................................. 9626 istrant is required to use the Adminis- (30) Hydroxypethidine .................................................... 9627 (31) Ketobemidone ........................................................ 9628 tration Controlled Substances Code (32) Levomoramide ........................................................ 9629 Number for any purpose. (33) Levophenacylmorphan ........................................... 9631 (34) 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4- [38 FR 8254, Mar. 30, 1973. Redesignated at 38 piperidyl]-N-phenylpropanamide) ............................... 9813 FR 26609, Sept. 24, 1973 and amended at 51 FR (35) 3-methylthiofentanyl (N-[(3-methyl-1-(2- 15318, Apr. 23, 1986; 62 FR 13968, Mar. 24, 1997] thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide) ..... 9833 (36) Morpheridine .......................................................... 9632 SCHEDULES (37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine) 9661 (38) Noracymethadol ..................................................... 9633 (39) Norlevorphanol ....................................................... 9634 § 1308.11 Schedule I. (40) Normethadone ........................................................ 9635 (a) Schedule I shall consist of the (41) Norpipanone ........................................................... 9636 (42) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2- drugs and other substances, by what- phenethyl)-4-piperidinyl] propanamide ....................... 9812 ever official name, common or usual (43) PEPAP (1-(-2-phenethyl)-4-phenyl-4- name, chemical name, or brand name acetoxypiperidine ....................................................... 9663 designated, listed in this section. Each (44) Phenadoxone ......................................................... 9637 (45) Phenampromide ..................................................... 9638 drug or substance has been assigned (46) Phenomorphan ....................................................... 9647 the DEA Controlled Substances Code (47) Phenoperidine ........................................................ 9641 Number set forth opposite it. (48) Piritramide .............................................................. 9642 (49) Proheptazine .......................................................... 9643 (b) Opiates. Unless specifically ex- (50) Properidine ............................................................. 9644 cepted or unless listed in another (51) Propiram ................................................................. 9649 schedule, any of the following opiates, (52) Racemoramide ....................................................... 9645 including their isomers, esters, ethers, (53) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4- piperidinyl]-propanamide ............................................ 9835 salts, and salts of isomers, esters and (54) Tilidine .................................................................... 9750 ethers, whenever the existence of such (55) Trimeperidine ......................................................... 9646 isomers, esters, ethers and salts is pos- (c) Opium derivatives. Unless specifi- sible within the specific chemical des- cally excepted or unless listed in an- ignation (for purposes of paragraph other schedule, any of the following (b)(34) only, the term isomer includes opium derivatives, its salts, isomers, the optical and geometric isomers): and salts of isomers whenever the ex- (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2- istence of such salts, isomers, and salts phenethyl)-4-piperidinyl]-N-phenylacetamide) ............ 9815 (2) Acetylmethadol ......................................................... 9601 of isomers is possible within the spe- (3) Allylprodine ............................................................... 9602 cific chemical designation: 82 VerDate 11<MAY>2000 08:46 May 09, 2001 Jkt 194070 PO 00000 Frm 00082 Fmt 8010 Sfmt 8010 Y:\SGML\194070T.XXX pfrm13 PsN: 194070T Drug Enforcement Administration, Justice § 1308.11 (1) Acetorphine .............................................................. 9319 (12) N-hydroxy-3,4-methylenedioxyamphetamine (also (2) Acetyldihydrocodeine ............................................... 9051 known as N-hydroxy-alpha-methyl- (3) Benzylmorphine ........................................................ 9052 3,4(methylenedioxy)phenethylamine, and N-hydroxy (4) Codeine methylbromide ........................................... 9070 MDA ........................................................................... 7402 (13) 3,4,5-trimethoxy amphetamine ............................... 7390 (5) Codeine-N-Oxide ...................................................... 9053 (14) Bufotenine .............................................................. 7433 (6) Cyprenorphine .......................................................... 9054 Some trade and other names: 3-(β (7) Desomorphine .......................................................... 9055 -Dimethylaminoethyl)-5-hydroxyindole; 3-(2- (8) Dihydromorphine ...................................................... 9145 dimethylaminoethyl)-5-indolol; N, N- (9) Drotebanol ................................................................ 9335 dimethylserotonin; 5-hydroxy-N,N- (10) Etorphine (except hydrochloride salt) .................... 9056 dimethyltryptamine; mappine (11) Heroin ..................................................................... 9200 (15) Diethyltryptamine .................................................... 7434 (12) Hydromorphinol ...................................................... 9301 Some trade and other names: N,N- (13) Methyldesorphine ................................................... 9302 Diethyltryptamine; DET (14) Methyldihydromorphine .......................................... 9304 (16) Dimethyltryptamine ................................................. 7435 (15) Morphine methylbromide ........................................ 9305 Some trade or other names: DMT (16) Morphine methylsulfonate ...................................... 9306 (17) Ibogaine .................................................................
Load more

Recommended publications
  • Controlled Substances Included. [M.S.A
    1998 PUBLIC AND LOCAL ACTS [No. 319] (HB 4065) AN ACT to amend 1978 PA 368, entitled “An act to protect and promote the public health; to codify, revise, consolidate, classify, and add to the laws relating to public health; to provide for the prevention and control of diseases and disabilities; to provide for the classification, administration, regulation, financing, and maintenance of personal, environ- mental, and other health services and activities; to create or continue, and prescribe the powers and duties of, departments, boards, commissions, councils, committees, task forces, and other agencies; to prescribe the powers and duties of governmental entities and officials; to regulate occupations, facilities, and agencies affecting the public health; to regulate health maintenance organizations and certain third party administrators and insurers; to provide for the imposition of a regulatory fee; to promote the efficient and economical delivery of health care services, to provide for the appropriate utilization of health care facilities and services, and to provide for the closure of hospitals or consolidation of hospitals or services; to provide for the collection and use of data and information; to provide for the transfer of property; to provide certain immunity from liability; to regulate and prohibit the sale and offering for sale of drug paraphernalia under certain circumstances; to provide for penalties and remedies; to provide for sanctions for violations of this act and local ordinances; to repeal certain acts and parts of acts; to repeal certain parts of this act; and to repeal certain parts of this act on specific dates,” by amending sections 7218 and 7401 (MCL 333.7218 and 333.7401), section 7401 as amended by 1996 PA 249, and by adding section 7401a.
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun
    CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun. 23, 2011, P.L. 36, No. 7 Cl. 35 Session of 2011 No. 2011-7 SB 1006 AN ACT Amending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for Schedule I controlled substances. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. Section 4(1) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, amended November 24, 1999 (P.L.894, No.55), is amended to read: Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. (1) Schedule I--In determining that a substance comes within this schedule, the secretary shall find: a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. The following controlled substances are included in this schedule: (i) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation: 1.
    [Show full text]
  • Proposed Regulation of the State Board of Pharmacy
    PROPOSED REGULATION OF THE STATE BOARD OF PHARMACY LCB File No. R133-14 Workshop July 24, 2014 NAC 453.540 Schedule IV. (NRS 453.146, 639.070) 1. Schedule IV consists of the drugs and other substances listed in this section, by whatever official, common, usual, chemical or trade name designated. 2. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs, including, without limitation, their salts, calculated as the free anhydrous base of alkaloid, is hereby enumerated on schedule IV, in quantities: (a) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit; or (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxy- butane). 3. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including, without limitation, their salts, isomers and salts of isomers, is hereby enumerated on schedule IV, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation: Alprazolam; Barbital; Bromazepam; Butorphanol; Camazepam; Carisoprodol; Chloral betaine; Chloral hydrate; Chlordiazepoxide; Clobazam; Clonazepam; Clorazepate; Clotiazepam; Cloxazolam; Delorazepam; Diazepam; Dichloralphenazone; Estazolam; Ethchlorvynol; Ethyl loflazepate; Fludiazepam; Flunitrazepam; --1-- Agency Draft of Proposed Regulation R133-14 Flurazepam; Halazepam; Haloxazolam; Ketazolam; Loprazolam; Lorazepam; Lormetazepam; Mebutamate; Medazepam; Meprobamate; Methohexital; Methylphenobarbital (mephobarbital); Midazolam; Nimetazepam; Nitrazepam; Nordiazepam; Oxazepam; Oxazolam; Paraldehyde; Petrichloral; Phenobarbital; Pinazepam; Prazepam; Quazepam; Tramadol (2-((dimethylamino)methyl)-1-(3-methoxyphenyl)cyclohexanol) Temazepam; Tetrazepam; Triazolam; Zaleplon; Zolpidem; or Zopiclone.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Telazol® CIII(Tiletamine and Zolazepam for Injection)
    TELAZOL- tiletamine hydrochloride and zolazepam hydrochloride injection, powder, for solution Zoetis Inc. ---------- Telazol® CIII (tiletamine and zolazepam for injection) 100 mg/mL total (equivalent to 50 mg/mL tiletamine and 50 mg/mL zolazepam) For Intramuscular and Intravenous injection in Dogs For Intramuscular injection only in Cats CAUTION Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. DESCRIPTION TELAZOL (tiletamine and zolazepam for injection) is a nonnarcotic, nonbarbiturate, injectable anesthetic agent for dogs and cats. Chemically, TELAZOL is a combination of equal parts by weight of base of tiletamine hydrochloride (2-[ethylamino]-2-[2-thienyl]-cyclohexanone hydrochloride), an arylaminocycloalkanone dissociative anesthetic, and zolazepam hydrochloride (4-[o-fluorophenyl]-6, 8-dihydro-1,3,8- trimethylpyrazolo [3, 4-e][1,4] diazepin-7 [1H]-1- hydrochloride), a nonphenothiazine diazepinone having minor tranquilizing properties. The product is supplied sterile in vials. The addition of 5 mL diluent produces a solution containing the equivalent of 50 mg tiletamine base, 50 mg zolazepam base and 57.7 mg mannitol per milliliter. This solution has a pH of 2 to 3.5 and is recommended for deep intramuscular injection. INDICATIONS Dogs TELAZOL is indicated in dogs for restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia. Minor surgery is considered to be laceration repair, draining of abscesses, castrations and other procedures requiring mild to moderate analgesia. (See Dogs under Dosage and Administration.) TELAZOL administered intravenously is indicated in dogs for induction of anesthesia followed by maintenance with an inhalant anesthetic. Cats TELAZOL is indicated in cats for restraint or for anesthesia combined with muscle relaxation.
    [Show full text]
  • 124.210 Schedule IV — Substances Included. 1
    1 CONTROLLED SUBSTANCES, §124.210 124.210 Schedule IV — substances included. 1. Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: a. Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. b. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- propionoxybutane). c. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 3. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a. Alprazolam. b. Barbital. c. Bromazepam. d. Camazepam. e. Carisoprodol. f. Chloral betaine. g. Chloral hydrate. h. Chlordiazepoxide. i. Clobazam. j. Clonazepam. k. Clorazepate. l. Clotiazepam. m. Cloxazolam. n. Delorazepam. o. Diazepam. p. Dichloralphenazone. q. Estazolam. r. Ethchlorvynol. s. Ethinamate. t. Ethyl Loflazepate. u. Fludiazepam. v. Flunitrazepam. w. Flurazepam. x. Halazepam. y. Haloxazolam. z. Ketazolam. aa. Loprazolam. ab. Lorazepam. ac. Lormetazepam. ad. Mebutamate. ae. Medazepam. af. Meprobamate. ag. Methohexital. ah. Methylphenobarbital (mephobarbital).
    [Show full text]
  • Veterinary Anesthetic and Analgesic Formulary 3Rd Edition, Version G
    Veterinary Anesthetic and Analgesic Formulary 3rd Edition, Version G I. Introduction and Use of the UC‐Denver Veterinary Formulary II. Anesthetic and Analgesic Considerations III. Species Specific Veterinary Formulary 1. Mouse 2. Rat 3. Neonatal Rodent 4. Guinea Pig 5. Chinchilla 6. Gerbil 7. Rabbit 8. Dog 9. Pig 10. Sheep 11. Non‐Pharmaceutical Grade Anesthetics IV. References I. Introduction and Use of the UC‐Denver Formulary Basic Definitions: Anesthesia: central nervous system depression that provides amnesia, unconsciousness and immobility in response to a painful stimulation. Drugs that produce anesthesia may or may not provide analgesia (1, 2). Analgesia: The absence of pain in response to stimulation that would normally be painful. An analgesic drug can provide analgesia by acting at the level of the central nervous system or at the site of inflammation to diminish or block pain signals (1, 2). Sedation: A state of mental calmness, decreased response to environmental stimuli, and muscle relaxation. This state is characterized by suppression of spontaneous movement with maintenance of spinal reflexes (1). Animal anesthesia and analgesia are crucial components of an animal use protocol. This document is provided to aid in the design of an anesthetic and analgesic plan to prevent animal pain whenever possible. However, this document should not be perceived to replace consultation with the university’s veterinary staff. As required by law, the veterinary staff should be consulted to assist in the planning of procedures where anesthetics and analgesics will be used to avoid or minimize discomfort, distress and pain in animals (3, 4). Prior to administration, all use of anesthetics and analgesic are to be approved by the Institutional Animal Care and Use Committee (IACUC).
    [Show full text]
  • Revise Schedule of Controlled Substances. (Public) Sponsors: Senators J
    GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 S 1 SENATE BILL 347* Short Title: Revise Schedule of Controlled Substances. (Public) Sponsors: Senators J. Davis, McInnis (Primary Sponsors); and Rabin. Referred to: Rules and Operations of the Senate March 22, 2017 1 A BILL TO BE ENTITLED 2 AN ACT REVISING THE SCHEDULE OF CONTROLLED SUBSTANCES TO ADD 3 SYNTHETIC FENTANYLS, DESIGNER HALLUCINOGENICS, SYNTHETIC 4 CANNABINOIDS, SYSTEM DEPRESSANTS, AND OTHER SUBSTANCES. 5 The General Assembly of North Carolina enacts: 6 SECTION 1. This act shall be known and may be cited as the "Synthetic Opioid 7 and Other Dangerous Drug Control Act." 8 SECTION 2. G.S. 90-89 reads as rewritten: 9 "§ 90-89. Schedule I controlled substances. 10 This schedule includes the controlled substances listed or to be listed by whatever official 11 name, common or usual name, chemical name, or trade name designated. In determining that a 12 substance comes within this schedule, the Commission shall find: a high potential for abuse, no 13 currently accepted medical use in the United States, or a lack of accepted safety for use in 14 treatment under medical supervision. The following controlled substances are included in this 15 schedule: 16 (1) Opiates. – Any of the following opiates, including the isomers, esters, ethers, 17 salts and salts of isomers, esters, and ethers, unless specifically excepted, or 18 listed in another schedule, whenever the existence of such isomers, esters, 19 ethers, and salts is possible within the specific chemical designation: 20 a. Acetyl-alpha-methylfentanyl 21 (N[1-(1-methyl-2-phenethyl)-4/y-piperidinyl]-N-phenylacet amide).
    [Show full text]
  • Introduced B.,Byhansen, 16
    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
    [Show full text]
  • 212102Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212102Orig1s000 OTHER REVIEW(S) Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research | Office of Surveillance and Epidemiology (OSE) Epidemiology: ARIA Sufficiency Date: June 29, 2020 Reviewer: Silvia Perez-Vilar, PharmD, PhD Division of Epidemiology I Team Leader: Kira Leishear, PhD, MS Division of Epidemiology I Division Director: CAPT Sukhminder K. Sandhu, PhD, MPH, MS Division of Epidemiology I Subject: ARIA Sufficiency Memo for Fenfluramine-associated Valvular Heart Disease and Pulmonary Arterial Hypertension Drug Name(s): FINTEPLA (Fenfluramine hydrochloride, ZX008) Application Type/Number: NDA 212102 Submission Number: 212102/01 Applicant/sponsor: Zogenix, Inc. OSE RCM #: 2020-953 The original ARIA memo was dated June 23, 2020. This version, dated June 29, 2020, was amended to include “Assess a known serious risk” as FDAAA purpose (per Section 505(o)(3)(B)) to make it consistent with the approved labeling. The PMR development template refers to the original memo, dated June 23, 2020. Page 1 of 13 Reference ID: 46331494640015 EXECUTIVE SUMMARY (place “X” in appropriate boxes) Memo type -Initial -Interim -Final X X Source of safety concern -Peri-approval X X -Post-approval Is ARIA sufficient to help characterize the safety concern? Safety outcome Valvular Pulmonary heart arterial disease hypertension (VHD) (PAH) -Yes -No X X If “No”, please identify the area(s) of concern. -Surveillance or Study Population X X -Exposure -Outcome(s) of Interest X X -Covariate(s) of Interest X X -Surveillance Design/Analytic Tools Page 2 of 13 Reference ID: 46331494640015 1.
    [Show full text]
  • 16.19.20 Nmac 1 Title 16 Occupational And
    TITLE 16 OCCUPATIONAL AND PROFESSIONAL LICENSING CHAPTER 19 PHARMACISTS PART 20 CONTROLLED SUBSTANCES 16.19.20.1 ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy. [16.19.20.1 NMAC - Rp 16.19.20.1 NMAC, 06-26-2018] 16.19.20.2 SCOPE: All persons or entities that manufacture, distribute, dispense, administer, prescribe, deliver, analyze, or conduct research using controlled substances. [16.19.20.2 NMAC - Rp 16.19.20.2 NMAC, 06-26-2018] 16.19.20.3 STATUTORY AUTHORITY: Section 30-31-11 of the Controlled Substances Act, 30-31-1 through 30-31-42 NMSA 1978, authorizes the board of pharmacy to promulgate regulations and charge reasonable fees for the registration and control of the manufacture, distribution and dispensing of controlled substances. [16.19.20.3 NMAC - Rp 16.19.20.3 NMAC, 06-26-2018] 16.19.20.4 DURATION: Permanent. [16.19.20.4 NMAC - Rp 16.19.20.4 NMAC, 06-26-2018] 16.19.20.5 EFFECTIVE DATE: June 26, 2018, unless a different date is cited at the end of a section. [16.19.20.5 NMAC - Rp 16.19.20.5 NMAC, 06-26-2018] 16.19.20.6 OBJECTIVE: The objective of Part 20 of Chapter 19 is to protect the public health and welfare of the citizens of New Mexico by controlling and monitoring access to controlled substances and to give notice of the board’s designation of particular substances as controlled substances. [16.19.20.6 NMAC - Rp 16.19.20.6 NMAC, 06-26-2018] 16.19.20.7 DEFINITIONS: [RESERVED] [16.19.20.7 NMAC - Rp 16.19.20.7 NMAC, 06-26-2018] 16.19.20.8 REGISTRATION REQUIREMENTS: Persons required to register: A.
    [Show full text]